Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Howard Rutman is active.

Publication


Featured researches published by Howard Rutman.


Circulation | 1986

Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure.

Joseph Gage; Howard Rutman; David Lucido; Thierry H. LeJemtel

The effects of amrinone, dobutamine, and a combination of the two drugs on peak positive left ventricular dP/dt and left ventricular performance were evaluated in 11 patients with chronic congestive heart failure. When administered alone, both dobutamine (10.9 micrograms/kg/min) and intravenous amrinone (1.9 mg/kg/min) significantly increased left ventricular dP/dt and performance. When compared with dobutamine alone, the addition of amrinone resulted in further increases in left ventricular dP/dt and cardiac index (to 1319 +/- 419 from 1202 +/- 376 mm Hg/sec, p less than .002, and to 3.56 +/- 0.78 from 3.04 +/- 0.67 liters/min/m2, p less than .01, respectively). The combination also induced a further reduction in left ventricular end-diastolic pressure (to 15.3 +/- 11.3 from 18.2 +/- 10.3 mm Hg, p less than .05) when compared with amrinone alone. The combination of dobutamine and amrinone increased heart rate slightly when compared with either drug alone, but did not further reduce systemic arterial pressure when compared with amrinone alone. The dose-response curve of left ventricular dP/dt and performance during titration of dobutamine with and without the addition of intravenous amrinone was evaluated in seven patients. The addition of amrinone to any dose of dobutamine produced higher cardiac index and lower systemic vascular resistance than dobutamine or amrinone alone. Thus, when compared with dobutamine alone in patients with chronic congestive heart failure, the addition of intravenous amrinone to dobutamine results in an additive improvement in left ventricular performance throughout the dose range.


European Heart Journal | 2015

Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation

Michelle L. O'Donoghue; Christian T. Ruff; Robert P. Giugliano; Sabina A. Murphy; Laura T. Grip; Michele Mercuri; Howard Rutman; Minggao Shi; Grzegorz Kania; Ondrej Cermak; Eugene Braunwald; Elliott M. Antman

AIMS Edoxaban is an oral, once-daily factor Xa inhibitor that is non-inferior to well-managed warfarin in patients with atrial fibrillation (AF) for the prevention of stroke and systemic embolic events (SEEs). We examined the efficacy and safety of edoxaban vs. warfarin in patients who were vitamin K antagonist (VKA) naive or experienced. METHODS AND RESULTS ENGAGE AF-TIMI 48 randomized 21 105 patients with AF at moderate-to-high risk of stroke to once-daily edoxaban vs. warfarin. Subjects were followed for a median of 2.8 years. The primary efficacy endpoint was stroke or SEE. As a pre-specified subgroup, we analysed outcomes for those with or without prior VKA experience (>60 consecutive days). Higher-dose edoxaban significantly reduced the risk of stroke or SEE in patients who were VKA naive [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.56-0.90] and was similar to warfarin in the VKA experienced (HR 1.01, 95% CI 0.82-1.24; P interaction = 0.028). Lower-dose edoxaban was similar to warfarin for stroke or SEE prevention in patients who were VKA naive (HR 0.92, 95% CI 0.73-1.15), but was inferior to warfarin in those who were VKA experienced (HR 1.31, 95% 1.08-1.60; P interaction = 0.019). Both higher-dose and lower-dose edoxaban regimens significantly reduced the risk of major bleeding regardless of prior VKA experience (P interaction = 0.90 and 0.71, respectively). CONCLUSION In patients with AF, edoxaban appeared to demonstrate greater efficacy compared with warfarin in patients who were VKA naive than VKA experienced. Edoxaban significantly reduced major bleeding compared with warfarin regardless of prior VKA exposure.


Journal of the American Heart Association | 2016

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial

Alon Eisen; Christian T. Ruff; Eugene Braunwald; Francesco Nordio; Ramón Corbalán; Anthony J. Dalby; Maria Dorobantu; Michele Mercuri; Hans Lanz; Howard Rutman; Stephen D. Wiviott; Elliott M. Antman; Robert P. Giugliano

Background Recent findings suggest that atrial fibrillation is associated with sudden cardiac death (SCD). We examined the incidence, characteristics, and factors associated with SCD in patients with atrial fibrillation. Methods and Results SCD was defined as witnessed death ≤60 minutes from the onset of new symptoms or unwitnessed death 1 to 24 hours after being observed alive, without another known cause of death. Predictors of SCD were examined using multivariate competing risks models. Over 2.8 years (median), 2349 patients died (40.5 per 1000 patient‐years), of which 1668 (71%) were cardiovascular deaths. SCD was the most common cause of cardiovascular death (n=749; median age 73 years; 70.6% male). Most SCD events occurred out of hospital (92.8%) and without prior symptoms (66.0%). Predictors of SCD included low ejection fraction, heart failure, and prior myocardial infarction (P<0.001 for each). Additional significant baseline predictors of SCD, but not of other causes of death, included male sex, electrocardiographic left ventricular hypertrophy, higher heart rate, nonuse of beta blockers, and use of digitalis. The latter was associated with SCD in patients with or without heart failure (adjusted hazard ratio 1.55 [95% CI 1.29–1.86] and 1.56 [95% CI 1.14–2.11], respectively; P interaction=0.73). The rate of SCD was numerically but not statistically lower with edoxaban (1.20% per year with lower dose edoxaban; 1.28% per year with higher dose edoxaban) compared with warfarin (1.40% per year). Conclusion SCD is the most common cause of cardiovascular death in patients with atrial fibrillation and has several distinct predictors, some of which are modifiable. These findings may be considered in planning research and treatment strategies for patients with atrial fibrillation. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT00781391.


American Heart Journal | 2016

Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–TIMI 48) trial

Alon Eisen; Robert P. Giugliano; Christian T. Ruff; Francesco Nordio; Harinder S. Gogia; Vivek R. Awasty; David A. Henderson; Michele Mercuri; Howard Rutman; Elliott M. Antman; Eugene Braunwald

BACKGROUND Edoxaban is a specific anti-Xa inhibitor that, in comparison to warfarin, has been found to be noninferior for the prevention of stroke or systemic embolism (SSE) and to reduce bleeding significantly in patients with nonvalvular atrial fibrillation (AF). The US Food and Drug Administration (FDA) approved the higher-dose edoxaban regimen (60/30 mg) in patients with AF and a creatinine clearance of ≤95 mL/min. We report for the first time the clinical characteristics, efficacy, and safety of the FDA-approved population in the ENGAGE AF--TIMI 48 trial. METHODS The patients included had been treated with either warfarin or edoxaban 60/30 mg and had a creatinine clearance of ≤95 mL/min. The primary efficacy was SSE, and the principal safety end point was major bleeding (International Society on Thrombosis and Haemostasis classification). Median follow-up was 2.8 years. RESULTS Patients in the FDA-approved cohort were older, were more likely female, and had higher CHADS2 and HAS-BLED scores, as compared with patients not included in the FDA label. The primary end point occurred in 1.63%/y with edoxaban vs 2.02%/y with warfarin (hazard ratio [HR] 0.81, 95% CI 0.67-0.97, P = .023). Edoxaban significantly reduced the rate of hemorrhagic stroke (HR 0.47, 95% CI 0.31-0.72, P < .001) and cardiovascular death (HR 0.84, 95% CI 0.73-0.97, P = .015). Ischemic stroke rates were similar between the treatment groups (1.31%/y vs 1.39%/y, P = .97). Major bleeding was significantly lower with edoxaban (3.16%/y vs 3.77%/y; HR 0.84, 95% CI 0.72-0.98, P = .023). CONCLUSION In the FDA-approved cohort of the ENGAGE AF--TIMI 48 trial, treatment with edoxaban 60/30 mg was superior to warfarin in the prevention of SSE and significantly reduced cardiovascular death and bleeding, especially fatal bleeding and hemorrhagic stroke.


Journal of the American Heart Association | 2017

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial

Alon Eisen; Christian T. Ruff; Eugene Braunwald; Rose A. Hamershock; Basil S. Lewis; Christian Hassager; Tze Fan Chao; Jean Yves Le Heuzey; Michele Mercuri; Howard Rutman; Elliott M. Antman; Robert P. Giugliano

Background Digoxin is widely used in patients with atrial fibrillation despite the lack of randomized controlled trials. Observational studies report conflicting results regarding its association with mortality, perhaps because of residual confounding by the presence of heart failure (HF). Methods and Results In the ENGAGE AF‐TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation‐Thrombolysis in Myocardial Infarction 48) trial, clinical outcomes of patients with atrial fibrillation with and without HF were examined by baseline digoxin use during a median follow‐up of 2.8 years. HF was defined at baseline as prior or current clinical stage C or D HF. Of 21 105 patients enrolled, 6327 (30%) were treated with digoxin at baseline. Among patients without HF (n=8981), digoxin use (20%) was independently associated with sudden cardiac death (adjusted hazard ratio, 1.51; 95% CI, 1.10–2.08), with no significant interaction by age, sex, left ventricular ejection fraction, renal function, or concomitant medications (P>0.05 for each). Consistent results were observed using propensity matching (adjusted hazard ratio for sudden cardiac death, 1.90; 95% CI, 1.36–2.65). Among patients with HF (n=12 124), digoxin use (37%) was associated with an increase in all‐cause death, cardiovascular death, sudden cardiac death, and death caused by HF/cardiogenic shock (P<0.01 for each), but not with noncardiovascular death, stroke/systemic embolism, or myocardial infarction. Conclusions In this observational analysis of patients with atrial fibrillation without investigator‐reported HF, digoxin use was significantly associated with sudden cardiac death. While residual confounding cannot be excluded, the association between digoxin use and worse clinical outcomes highlights the need to examine digoxin use, particularly when prescribed to control heart rate in patients with atrial fibrillation in a randomized trial. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781391.


International Journal of Cardiology | 2018

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial

Ilaria Cavallari; Christian T. Ruff; Francesco Nordio; Naveen Deenadayalu; Minggao Shi; Hans Lanz; Howard Rutman; Michele Mercuri; Elliott M. Antman; Eugene Braunwald; Robert P. Giugliano

BACKGROUND Patients with atrial fibrillation (AF) who interrupt anticoagulation are at high risk of thromboembolism and death. METHODS AND RESULTS Patients enrolled in the ENGAGE AF-TIMI 48 trial (randomized comparison of edoxaban vs. warfarin) who interrupted study anticoagulant for >3 days were identified. Clinical events (ischemic stroke/systemic embolism, major cardiac and cerebrovascular events [MACCE]) were analyzed from day 4 after interruption until day 34 or study drug resumption. During 2.8 years median follow-up, 13,311 (63%) patients interrupted study drug for >3 days. After excluding those who received open-label anticoagulation during the at-risk window, the population for analysis included 9148 patients. The rates of ischemic stroke/systemic embolism and MACCE post interruption were substantially greater than in patients who never interrupted (15.42 vs. 0.26 and 60.82 vs. 0.36 per 100 patient-years, respectively, padj < .001). Patients who interrupted study drug for an adverse event (44.1% of the cohort), compared to those who interrupted for other reasons, had an increased risk of MACCE (HRadj 2.75; 95% CI 2.02-3.74, p < .0001), but similar rates of ischemic stroke/systemic embolism. Rates of clinical events after interruption of warfarin and edoxaban were similar. CONCLUSION Interruption of study drug was frequent in patients with AF and was associated with a substantial risk of major cardiac and cerebrovascular events over the ensuing 30 days. This risk was particularly high in patients who interrupted as a result of an adverse event; these patients deserve close monitoring and resumption of anticoagulation as soon as it is safe to do so.


American Heart Journal | 2018

Stroke prevention in atrial fibrillation: Closing the gap

Sean D. Pokorney; Bernard J. Gersh; Azhar Ahmad; Sana M. Al-Khatib; Melanie Blank; Megan Coylewright; Peter M. DiBattiste; Jeff S. Healey; Olaf Hedrich; Elaine M. Hylek; Eva Kline-Rogers; Eric D. Peterson; Phil Mendys; Michael J. Mirro; Gerald V. Naccarelli; Parashar Patel; Christian T. Ruff; Howard Rutman; Norman Stockbridge; Robert Temple; Christopher B. Granger

Stroke prevention in atrial fibrillation: Closing the gap Sean D. Pokorney, MD, MBA, a Bernard J. Gersh, MB, ChB, b Azhar Ahmad, MD, c Sana M. Al-Khatib, MD, MHS, a Melanie Blank, MD, d Megan Coylewright, MD, MPH, e Peter DiBattiste, MD, f Jeff S. Healey, MD, g Olaf Hedrich, MD, h Elaine M. Hylek, MD, MPH, i Eva Kline-Rogers, RN, NP, j Eric D. Peterson, MD, MPH, a Phil Mendys, PharmD, k Michael J. Mirro, MD, l Gerald Naccarelli, MD, Parashar Patel, MPA, h Christian T. Ruff, MD, MPH, n Howard Rutman, MD, o Norman Stockbridge, MD, PhD, d Robert Temple, MD, d and Christopher B. Granger, MD a Durham, Chapel Hill, NC; Rochester, MN; Ridgefield, CT; Silver Spring, MD; Lebanon, NH; Raritan, Basking Ridge, NJ; Ontario, Canada; Marlborough, Boston, MA; Ann Arbor, MI; and Hershey, PA


Circulation | 2014

Abstract 12680: Efficacy and Safety of Edoxaban Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure: Insights From Engage-AF TIMI 48

Giulia Magnani; Robert P. Giugliano; Christian T. Ruff; Sabina A. Murphy; Francesco Nordio; Howard Rutman; Valentin Curt; Minggao Shi; Michele Mercuri; Eugene Braunwald; Elliott M. Antman


European Heart Journal | 2018

P285Comparison of analysis methodologies for net outcome with edoxaban vs warfarin in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial

R.A. Hamershock; R. De Caterina; Elliot M. Antman; Sabina A. Murphy; Christian T. Ruff; Howard Rutman; Michele Mercuri; H Lanz; Eugene Braunwald; Robert P. Giugliano


Circulation | 2016

Abstract 16993: Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation Without Heart Failure in the ENGAGE AF-TIMI 48 Trial

Alon Eisen; Christian T. Ruff; Eugene Braunwald; Rose Hamershock; Basil S. Lewis; Christian Hassager; Jean Yves LeHeuzey; Michele Mercuri; Howard Rutman; Elliott M. Antman; Robert P. Giugliano

Collaboration


Dive into the Howard Rutman's collaboration.

Top Co-Authors

Avatar

Christian T. Ruff

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Eugene Braunwald

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Robert P. Giugliano

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elliott M. Antman

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Francesco Nordio

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sabina A. Murphy

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge